A retrospective study assessing the pathologic response of trastuzumab ± pertuzumab in patients with ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Latest Information Update: 10 Aug 2021
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Ductal carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 10 Aug 2021 New trial record
- 01 Aug 2021 Results published in the Breast Cancer Research and Treatment